Peripheral T Cell Lymphoma clinical trials

Explore recruiting peripheral t cell lymphoma clinical trials.

Recruiting peripheral t cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Peripheral T Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

Spain, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma

Poland, Germany, Italy, Spain, Hungary

Phase II and Phase III (Integrated) EU CTIS Study details

Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Belgium, Spain, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Peripheral T Cell Lymphoma trials by city

Peripheral T Cell Lymphoma in Toronto Peripheral T Cell Lymphoma in Vancouver Peripheral T Cell Lymphoma in Montreal Peripheral T Cell Lymphoma in Calgary Peripheral T Cell Lymphoma in Edmonton Peripheral T Cell Lymphoma in Ottawa Peripheral T Cell Lymphoma in Winnipeg Peripheral T Cell Lymphoma in Quebec City Peripheral T Cell Lymphoma in Hamilton Peripheral T Cell Lymphoma in Kitchener Peripheral T Cell Lymphoma in London Peripheral T Cell Lymphoma in Halifax Peripheral T Cell Lymphoma in New York Peripheral T Cell Lymphoma in Los Angeles Peripheral T Cell Lymphoma in Chicago Peripheral T Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease